<DOC>
	<DOCNO>NCT00425841</DOCNO>
	<brief_summary>RATIONALE : Stereotactic radiation therapy may able send x-ray directly tumor cause less damage normal tissue . Drugs use chemotherapy , gemcitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving stereotactic radiation therapy together combination chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving combination chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give stereotactic radiation therapy together combination chemotherapy work treat patient undergo surgery locally advance pancreatic cancer .</brief_summary>
	<brief_title>Stereotactic Radiation Therapy Combination Chemotherapy Treating Patients Undergoing Surgery Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical response rate patient undergo surgery locally advance pancreatic cancer treat stereotactic radiotherapy , gemcitabine hydrochloride , oxaliplatin . Secondary - Determine toxicity regimen patient . - Determine time disease progression patient treat regimen . - Determine time death patient treat regimen . - Determine perioperative morbidity mortality patient treat regimen . - Determine rate R0 resections patient treated regimen . - Determine histologic response rate patient . OUTLINE : - Neoadjuvant therapy : Patients undergo hypofractionated , stereotactic radiotherapy day 1-5 . Patients also receive gemcitabine hydrochloride IV 100 minute day 1 oxaliplatin IV 120 minute day 2 . Treatment gemcitabine hydrocloride oxaliplatin repeat every 2 week 3 course . - Surgery : Patients resectable disease undergo tumor resection . Patients unresectable disease undergo second course neoadjuvant chemoradiotherapy follow resection . - Adjuvant therapy : Beginning 3-4 week surgery , patient receive 3 course chemotherapy neoadjuvant therapy . After completion study treatment , patient follow every 3 month 2 year . PROJECTED ACCRUAL : A total 29 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas intrapancreatic bile duct carcinoma Overall view image morphology CA199 ( &lt; 500 U/L ) demonstrate pancreatic cancer allow histologic/cytologic confirmation unavailable Locally advance disease , meet 1 follow criterion : Uncertain R0 resectability dependant relation portal vein , sinus confluens , superior mesenteric artery , superior mesenteric vein ( e.g. , contact portal vein , superior mesenteric vein , arterial vessel , &lt; 180° encasement ) Unresectable pancreatic cancer ( e.g. , contact portal vein , superior mesenteric artery arterial vessel , &gt; 180° encasement ) Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 1 cm spiral CT scan MRI Patients measurable disease may assess feasibility No distant metastases PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky PS 80100 % WBC ≥ 3,000/mm³ Granulocyte count ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Creatinine clearance &gt; 30 mL/min Bilirubin ≤ 3.0 time upper limit normal AST ALT ≤ 2.5 time normal Alkaline phosphatase ≤ 2.5 time normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No secondary malignancy within past 5 year curatively treat No know intolerance study drug No preexist polyneuropathy &gt; grade 1 No active uncontrolled infection No cardiac insufficiency despite optimal medication No New York Heart Association class III IV congestive heart failure LVEF ≥ 50 % OR shorten fraction ≥ 25 % No angina pectoris ( rest stress ) unexplained interventional cardiology within past 6 month No myocardial infarction within past 6 month No uncontrolled diabetes mellitus No exist serious medical impairment would preclude study compliance PRIOR CONCURRENT THERAPY : No prior chemotherapy No prior radiotherapy abdomen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
</DOC>